Metalloproteinases: their role in arthritis and potential as therapeutic targets

Expert Opin Ther Targets. 2003 Feb;7(1):19-34. doi: 10.1517/14728222.7.1.19.

Abstract

Irreversible degradation of articular cartilage is a major feature of the arthritides, and its prevention is a therapeutic goal which has been difficult to achieve. Enzymes from the matrix metalloproteinase and ADAMTS (a disintegrin, a metalloproteinase, and thrombospondin motif) families are key mediators of cartilage extracellular matrix destruction. Inhibition of metalloproteinase activity is therefore a conceptually attractive therapeutic strategy, although clinical efficacy has not yet been demonstrated. This review outlines the biology behind metalloproteinases as drug targets in the arthritides, and poses important questions for the future design of such therapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • ADAM Proteins / antagonists & inhibitors
  • ADAM Proteins / physiology
  • ADAM17 Protein
  • Animals
  • Arthritis / drug therapy*
  • Arthritis / enzymology
  • Arthritis, Experimental / drug therapy
  • Arthritis, Experimental / enzymology
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / enzymology
  • Cartilage, Articular / pathology
  • Drug Design
  • Drug Evaluation, Preclinical
  • Extracellular Matrix Proteins / metabolism
  • Humans
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases / physiology*
  • Mice
  • Minocycline / pharmacology
  • Minocycline / therapeutic use
  • Protease Inhibitors / pharmacology*
  • Protease Inhibitors / therapeutic use

Substances

  • Extracellular Matrix Proteins
  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
  • ADAM Proteins
  • Matrix Metalloproteinases
  • ADAM17 Protein
  • Minocycline